NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain. NV-387’s proposed mechanism targets viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
The announcement comes as health authorities work to contain the Ebola outbreak caused by the Bundibugyo species, which has a higher fatality rate than the Zaire strain. NanoViricides emphasized that NV-387 is designed to inhibit viral entry by mimicking cell surface receptors, a strategy that could be effective against multiple filoviruses. The company believes this broad-spectrum approach is critical for pandemic preparedness, as it could provide a rapid response to emerging viral threats without the need for strain-specific vaccines or treatments.
NanoViricides’ lead drug candidate, NV-387, is currently being developed for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company plans to advance NV-387 into Phase II human clinical trials. NV-CoV-2 (API NV-387) is a nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, the encapsulated version could be an approvable drug if safety is comparable.
NanoViricides also has a pipeline of drugs targeting herpes, viral eye diseases, influenza, HIV, hepatitis C, rabies, dengue, and Ebola, among others. The company’s platform technology is based on TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. For more information, visit https://ibn.fm/mm3Z5.
As with any drug development, there is no assurance that NV-387 or any other candidate will show sufficient effectiveness and safety for clinical development. The company acknowledges the lengthy and capital-intensive nature of drug development. For the latest news on NanoViricides, visit https://ibn.fm/NNVC.
This news matters because it underscores the ongoing need for broad-spectrum antivirals to combat emerging infectious diseases like Ebola, which pose significant public health threats. If NV-387 proves effective, it could represent a major advancement in pandemic preparedness, offering a single drug capable of treating multiple viral families.
